宣肺健脾方对慢性阻塞性肺疾病大鼠肺组织病理、气道杯状细胞及黏蛋白5AC的影响

doi:10.20047/j.issn1673-7210.2022.34.02

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (1202 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the effects of Xuanfei Jianpi Formula on the lung tissue pathology, airway goblet cells and Mucin5AC (MUC5AC) in rats with chronic obstructive pulmonary disease (COPD). Methods Forty Wistar male rats aged 10 to 12 weeks and weighing (230±20) g were divided into blank group, model group, traditional Chinese medicine group, and western medicine group according to random number table method, with ten rats in each group. Except the normal feeding of the blank group, the other groups were treated with lipopolysaccharide injection and smoked cigarettes to prepare COPD rat models. After the modeling, the traditional Chinese medicine group was given Xuanfei Jianpi Formula (1 ml/ 100 g), the western medicine group was given Mucosolvan (1 ml/100 g), and the blank and the model groups were given 0.9% normal saline for 14 consecutive days. Hematoxylin and eosin (HE) staining was performed to observe lung tissue pathology, and the total number and classification of white blood cells in bronchoalveolar lavage fluid (BALF) were detected. Goblet cells were observed by Alcian blue periodic acid-Schiff (AB-PAS) staining, and MUC5AC was detected by immunohistochemistry. Results The lung structure of blank group was complete, no inflammatory cell infiltration was observed, the lung structure destruction and inflammatory reaction were obvious in the model group, and the lung structure and inflammatory reaction were improved in the traditional Chinese medicine group compared with the model group. The total number of white blood cells, neutrophils and lymphocytes in BALF in model group were higher than those in blank group, and the differences were statistically significant (P＜0.05). The total number of white blood cells, neutrophils and lymphocytes in BALF in traditional Chinese medicine group were lower than those in model group, and the differences were statistically significant (P＜0.05). There were a few goblet cells occasionally in blank group, and the goblet cell proliferation in model group was higher than that in blank group. The goblet cell proliferation in the traditional Chinese medicine group and the western medicine group was lower than that in model group. The relative coloring area of model group was higher than that of the blank group, and the difference was statistically significant (P＜0.05). The relative coloring area of the traditional Chinese medicine group was lower than that of model group, and the difference was statistically significant (P＜0.05). The expression of MUC5AC protein in lung tissue of model group was higher than that of the blank group, and the difference was statistically significant (P＜0.05). The protein expression of MUC5AC in the traditional Chinese medicine group group was lower than that in the model group, and the difference was statistically significant (P＜0.05). Conclusion Xuanfei Jianpi Formula may down-regulate the expression of MUC5AC and reduce airway mucus hypersecretion by inhibiting goblet cell metaplasia. At the same time, it can reduce the pathological damage of lung tissue.

Key words： Chronic obstructive pulmonary disease Airway mucus hypersecretion Xuanfei Jianpi Formula Goblet cells Mucin5AC

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Xianli1 SHI Liqing2 MA Jianling2 JI Kun2 WEN Shaohui2 WANG Liangmin2 LI Yuan2 WEI Shuangyin2

Cite this article:

LI Xianli1 SHI Liqing2 MA Jianling2 JI Kun2 WEN Shaohui2 WANG Liangmin2 LI Yuan2 WEI Shuangyin2. Effects of Xuanfei Jianpi Formula on lung tissue pathology, airway goblet cells and Mucin5AC in rats with chronic obstructive pulmonary disease[J]. 中国医药导报, 2022, 19(34): 8-12.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2022.34.02 OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I34/8

[1] 周玲凤，何庆华，唐海，等.慢性阻塞性肺疾病流行病学调查及防控分析[J].中国医学创新，2021，18（6）：84-87.
[2] Szalontai K，Gémes N，Furák J，et al. Chronic Obstructive Pulmonary Disease：Epidemiology，Biomarkers，and Paving the Way to Lung Cancer [J]. J Clin Med，2021，10（13）：2889.
[3] Wang C，Xu J，Yang L，et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China（the China Pulmonary Health [CPH] study）：a national cross-sectional study [J]. Lancet，2018，391（10131）：1706-1717.
[4] 林展增.中国慢性阻塞性肺疾病流行病学研究进展[J].河北北方学院学报（自然科学版），2020，36（8）：49-51.
[5] 廖清，陶玉坚.慢性阻塞性肺疾病流行病学及危险因素研究现状[J].中华临床医师杂志（电子版），2018，12（8）：468-471.
[6] Stylianou P，Clark K，Gooptu B，et al. Tensin1 expression and function in chronic obstructive pulmonary disease [J]. Sci Rep，2019，9（1）：18942.
[7] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组，中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南（2021年修订版）[J].中华结核和呼吸杂志，2021，44（3）：170-205.
[8] Boucher RC. Muco-Obstructive Lung Diseases [J]. N Engl J Med，2019，380（20）：1941-1953.
[9] 张晶，王彬，高峰.中医药干预慢性阻塞性肺疾病气道黏液高分泌作用机制研究进展[J].国际中医中药杂志，2020， 42（10）：1040-1043.
[10] 吕明圣，张沂，张迪，等.中医药多靶点干预慢性阻塞性肺疾病机制研究概述[J].中医杂志，2019，60（19）：1697- 1700.
[11] 范英兰，朱竟赫，甘雨，等.慢性阻塞性肺疾病大鼠模型的建立与评价[J].实用中医内科杂志，2021，36（10）：27-29， 158-159.
[12] 何转霞，齐鑫鑫，刘涛.慢性阻塞性肺疾病的体内外实验模型研究进展[J].毒理学杂志，2022，36（1）：80-85.
[13] 马建岭，季坤，董尚娟，等.宣肺健脾方治疗COPD稳定期气道黏液高分泌的临床疗效观察[J].世界中医药，2020， 15（4）：578-581.
[14] 唐欣，万南生，杨夏，等.慢性气道黏液高分泌与慢性阻塞性肺疾病的研究进展[J].中华结核和呼吸杂志，2021， 44（6）：574-578.
[15] 蔡霜，邹文静，王婷，等.Brg1通过STAT6促进哮喘气道黏液高分泌[J].南方医科大学学报，2018，38（1）：42-47.
[16] 蔺林，戴飞，任国强，等.嗜中性粒细胞弹性蛋白酶体外促进嗜中性粒细胞型鼻息肉中MUC5AC合成和释放[J].中国免疫学杂志，2020，36（15）：1873-1876.
[17] Kim MD，Baumlin N，Dennis JS，et al. Losartan reduces cigarette smoke-induced airway inflammation and mucus hypersecretion [J]. ERJ Open Res，2021，7（1）：00394- 2020.
[18] 钟秀君，高丹丹，顾文燕，等.蠲饮泄肺方对脂多糖诱导的气道黏液高分泌MUC5AC表达的影响[J].国际呼吸杂志，2018，38（16）：1256-1260.
[19] 伍清华，陈瑞坤，彭芳，等.气道炎症在COPD发生发展中的研究进展[J].中国医药科学，2020，10（17）：48-52.
[20] Radicioni G，Ceppe A，Ford AA，et al. Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease：an analysis of the SPIROMICS cohort [J]. Lancet Respir Med，2021，9（11）：1241-1254.
[21] Singanayagam A，Footitt J，Marczynski M，et al. Airway mucins promote immunopathology in virus-exacerbated chronic obstructive pulmonary disease [J]. J Clin Invest，2022，132（8）：e120901.
[22] 陈翠仪，吴雷，吕嘉春，等.黏蛋白在哮喘-慢性阻塞性肺疾病重叠中的表达与临床意义[J].现代医学与健康研究电子杂志，2021，5（10）：23-25.
[23] Lin XG，Li W，Xiang SY，et al. Electroacupuncture improves lung function by suppressing mucin-5AC mediated EGFR-p38MAPK signaling and inflammation reaction in chronic obstructive pulmonary disease rats [J]. Zhen Ci Yan Jiu，2021，46（3）：180-186.
[24] Cheon YH，Kim MS，Kim JY，et al. Eupatilin downregulates phorbol 12-myristate 13-acetate-induced MUC5AC expression via inhibition of p38/ERK/JNK MAPKs signal pathway in human airway epithelial cells [J]. Korean J Physiol Pharmacol，2020，24（2）：157-163.
[25] Li J, Ye Z. The Potential Role and Regulatory Mechanisms of MUC5AC in Chronic Obstructive Pulmonary Disease [J]. Molecules，2020，25（19）：4437.
[26] Lee SU，Kim MO，Kang MJ，et al. Transforming Growth Factor beta Inhibits MUC5AC Expression by Smad3/ HDAC2 Complex Formation and NF-kappaB Deacetylation at K310 in NCI-H292 Cells [J]. Mol Cells，2021，44（1）：38-49.